25th week of 2011 patent applcation highlights part 49 |
Patent application number | Title | Published |
20110150770 | MULTIVALENT VACCINE AGAINST PORCINE TESCHOVIRUS AND OTHER DISEASE CAUSING ORGANISMS IN SWINE - An immunogenic composition or vaccine, and method of treatment are provided by the present invention. The immunogenic composition is useful for treating, preventing, and lessening the severity of clinical symptoms associated with disease-causing organisms in swine, utilizing one or more Porcine Teschovirus antigen(s) along with an antigen of the other disease-causing organism in swine and a pharmaceutically acceptable carrier. | 2011-06-23 |
20110150771 | CHIMERIC WEST NILE/DENGUE VIRUSES - The disclosure provides chimeric West Nile/Dengue viruses comprising non-coding regions, non-structural proteins, and a C protein from a West Nile virus and prM and E proteins from a Dengue virus. Also disclosed are methods of using the chimeric viruses in diagnosis of Dengue viral infection, assessment of candidate Dengue virus vaccine efficacy, and production of Dengue prM and E proteins. | 2011-06-23 |
20110150772 | MODULATORS OF CARNITINE OCTANOYLTRANSFERASE IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of carnitine octanoyltransferase (CROT), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 2011-06-23 |
20110150773 | MODULATORS OF ACETYL-COENZYME A ACYLTRANSFERASE 1 OR 2 IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of acetyl-coenzyme A acyltransferase 1 (ACAA1) or of acetyl-coenzyme A acyltransferase 2 (ACAA2), and also utilizes modulators of the expression or of the activity of either of these enzymes, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 2011-06-23 |
20110150774 | SCREENING FOR MODULATORS OF CES1 AND/OR CES3 FOR THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the carboxylesterase 1 (CES1) and/or carboxylesterase 3 (CES3) proteins. | 2011-06-23 |
20110150775 | GENOMIC APPROACHES TO FETAL TREATMENT AND DIAGNOSIS - The present invention provides systems for developing and/or testing therapies for prenatal diseases and conditions including Down Syndrome. The present invention also provides diagnostic methods for Down Syndrome involving, in some embodiments, gene expression analyses of fetal RNA and/or detection of expression of particular genes involved in Down Syndrome. Also provided are microarrays and kits useful in prenatal diagnostic applications. | 2011-06-23 |
20110150776 | Method for Testing and Treating Delayed Food Allergies - A method for testing, treating, and preventing delayed food allergies includes: receiving detailed symptom, medical, and dietary histories from a patient; formulating a combination of one or more food extracts at selected concentration for sublingual adminstration over a trial period; determining whether the patient's symptoms have improved, worsened, or had no change, in response to the administration of the combination; and altering the combination in response to whether the patient's symptoms have improved, worsened, or not changed, so as to induce immune system food tolerance. | 2011-06-23 |
20110150777 | Magnetic resonance tomography imaging - A medical magnetic resonance tomography apparatus and a contrast agent for magnetic resonance tomography imaging of cavities in a patient are provided. The contrast agent is formed from a highly viscous magnetic resonance contrast agent. The highly viscous magnetic resonance contrast agent includes a substance. A specific magnetic resonance contrast can be generated by the substance. | 2011-06-23 |
20110150778 | Assembly of Gas-Filled Microvesicle With Active Component For Contrast Imaging - Assembly comprising a gas-filled microvesicle and a structural entity which is capable to associate through an electrostatic interaction to the outer surface of said microvesicle (microvesicle associated component—MAC), thereby modifying the physico-chemical properties thereof. Said MAC comprises a targeting ligand a diagnostic agent or any combination thereof. Optionally a bioactive agent can further be associated to the MAC. The assembly of the invention can be formed from gas-filled microbubbles or microballoons and a MAC having preferably nanometric dimensions, e.g. a micelle, and is used as an active component in diagnostically and/or therapeutically active formulations, in particular for enhancing the imaging in the field of ultrasound contrast imaging, including targeted ultrasound imaging, ultrasound-mediated drug delivery and other imaging techniques such as molecular resonance imaging (MRI) or nuclear imaging. | 2011-06-23 |
20110150779 | DYNAMIC NUCLEAR POLARIZATION ENHANCED NUCLEAR MAGNETIC RESONANCE OF WATER UNDER AMBIENT CONDITIONS - A method and apparatus are provided for treating hydrated material in a fluid that contains water in which a stable nitroxide is attached to the hydrated material. A dynamic nuclear polarization process (DNP) is conducted on the hydrated material whereby to hyperpolarize the water. A polarization cell contains the hydrated material to obtain hyperpolarized water free from the nitroxide. The dynamic nuclear polarization process is conducted using components comprising a tunable, solid state high power X-band driver and an X-band resonator for microwave transmission to the hydrated material. The components can also include a radio-frequency nuclear magnetic resonance probe, a permanent magnet formed to receive the hydrated material, a portable nuclear magnetic resonance spectrometer, and an electron spin resonance detector. The components can be sized to be portable, and include electrical input and output and a lap-size hard-case with access to the electrical input and output. | 2011-06-23 |
20110150780 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS - Compositions and methods for treating infections, especially bacterial infections, are provided. Indolicidin peptide analogues containing at least two basic amino acids are prepared. The analogues are administered as modified peptides, preferably containing photo-oxidized solubilizer. | 2011-06-23 |
20110150781 | TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASE - The invention relates to methods of treating Parkinson's disease, dementia with Lewy bodies, and conditions associated with Parkinson's disease and dementia with Lewy bodies. Methods include administering a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof. | 2011-06-23 |
20110150782 | COMBINATION THERAPY FOR COPD - Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate. | 2011-06-23 |
20110150783 | AEROSOL FORMULATION FOR COPD - Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions. | 2011-06-23 |
20110150784 | COMBINATION THERAPY FOR COPD - Aerosol formulations comprising glycopyrronium chloride in combination with formoterol may be administered by means of a pressurized metered dose inhaler (pMDI) for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium chloride and the formoterol components. Optionally, the formulation may further comprise beclometasone dipropionate. | 2011-06-23 |
20110150785 | Light Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment - Methods of treating inflammatory conditions, disease and disorders are provided. Method include, for example, contacting or administering a sufficient amount of a LIGHT inhibitor to a subject to treat the inflammatory condition, disease or disorder. | 2011-06-23 |
20110150786 | COMPOSITION CONTAINING A VOLATILE LINEAR ALKANE, AN AMINATED SILICONE AND A VEGETABLE OIL - Composition containing, in a cosmetically acceptable medium, one or more volatile linear alkanes, at least 0.5 wt. % of one or more aminated silicones relative to the total weight of the cosmetic composition, and one or more vegetable oils different from the volatile linear alkanes. Use thereof for the treatment of keratinous materials, preferably of keratin fibres such as the hair. | 2011-06-23 |
20110150787 | LIQUID CLEANING AND/OR CLEANSING COMPOSITION - The present invention relates to a liquid, cleaning and/or cleansing composition comprising abrasive cleaning particles. | 2011-06-23 |
20110150788 | LIQUID CLEANING AND/OR CLEANSING COMPOSITION - The present invention relates to a liquid, cleaning and/or cleansing composition comprising abrasive cleaning particles. | 2011-06-23 |
20110150789 | ANTI-CALCULUS DENTAL COMPOSITION - The present invention relates generally to an anti-calculus composition and method for treating subgingival calculus. The anti-calculus composition comprises a pyrophosphate and a tripolyphosphate in a pharmaceutically acceptable carrier. The composition may also comprise a fluoride providing compound. | 2011-06-23 |
20110150790 | GLUCOSYLTRANSFERASE INHIBITOR CONTAINING EPIGALLOCATECHIN GALLATE POLYMER AS ACTIVE INGREDIENT - Provided is a highly palatable and safe glucosyltransferase inhibitor or anti-dental caries agent. A glucosyltransferase inhibitor or anti-dental caries agent having an epigallocatechin gallate polymer or a salt thereof. Particularly, the above agent containing an epigallocatechin gallate polymer, which is a compound in which chroman rings are bonded at position 6 and/or 8 via a methylene group. | 2011-06-23 |
20110150791 | CALCIUM PHOSPHATE COMPLEX FOR ORAL CARE APPLICATIONS, ITS PREPARATION METHOD, AND COMPOSITIONS CONTAINING THE SAME - The invention is directed to a calcium phosphate complex and the composition containing the same for oral care applications, in which the calcium phosphate complex is formed by chelating the γ-polyglutamic acid (γ-PGA) with amorphous calcium phosphate (ACP). This complex can prevent crystallization of ACP and maintain its high solubility. The calcium phosphate complex has superior mucoadhesion properties, allowing it to remain in the mouth longer and offering effective buffering, by which dental caries can be alleviated and prevented. | 2011-06-23 |
20110150792 | ZINC OXIDE AQUEOUS AND NON-AQUEOUS DISPERSIONS - Disclosed is a composition that comprises an aqueous or non-aqueous carrier and zinc oxide particles dispersed therein that have a primary particle size of 100 nm or greater with substantially no or few zinc oxide particles having a particle size less than 100 nm. | 2011-06-23 |
20110150793 | Clear or Translucent Composition - The present disclosure relates to a clear or translucent composition which takes the form of a solid, a semi-solid or a viscous gel. The inventive composition contains a mixture of at least two amino acid-based gelatinizing agents, a non-ionic unsaturated fatty alcohol in an amount which reduces the dissolution temperature of the gelatinizing agents to allow processing at or below 100° C., an alkyl dimethicone, and an oil and/or a polymer component. Additional ingredients depending on the application may also be included in the clear or translucent composition. The present disclosure also relates to methods of producing the clear or translucent composition of the disclosure and uses thereof. | 2011-06-23 |
20110150794 | Polymeric Compositions for Personal Care Products - A polymeric composition is disclosed for use in personal care products. The composition is, at room temperature, a solid solution of a long-chain alcohol having ten to fifty carbon atoms and a polyalkyl[meth]acrylate polymer having some alkyl side chains pendant the ester group having ten to thirty carbon atoms and other alkyl side chains pendant the ester group having one to eight carbon atoms. The polymer can be formed by a transesterification reaction of a polyalkyl[meth]acrylate and the long chain alcohol in the presence of a catalyst. | 2011-06-23 |
20110150795 | COSMETIC COMPOSITIONS COMPRISING EXOPOLYSACCHARIDES DERIVED FROM MICROBIAL MATS, AND USE THEREOF - Disclosed herein is a skin care composition comprising at least one exopolysaccharide (EPS) originating from a microbial mat, wherein the EPS is in a concentration of about 0.001% w/w to about 1.5 w/w of the composition. Preferably, the EPS is derived from microorganism isolated from microbial mats found in French Polynesia. The composition is useful in reducing and preventing signs of skin aging and environmental damage by altering skin cell metabolism and improving hydration. | 2011-06-23 |
20110150796 | PRECIPITATION POLYMERIZATION IN THE PRESENCE OF GLYCERIN MONOSTEARATE - A process for preparing a copolymer composition A) by free-radical copolymerization of a monomer composition comprising: a) acrylic acid, b) optionally at least one compound, different from a), having a free-radically polymerizable, α,β-ethylenically unsaturated double bond and at least one anionogenic and/or anionic group per molecule, c) at least one free-radically polymerizable crosslinking compound which comprises at least two α,β-ethylenically unsaturated double bonds per molecule. The process is performed by precipitation polymerization in the presence of an auxiliary composition H) comprising H1) glycerol monostearate, and H2) at least one compound with an HLB value in the range from 4 to 10, selected from water-insoluble natural waxes, nonionic emulsifiers and mixtures thereof. | 2011-06-23 |
20110150797 | COMPOSITION COMPRISING AN ALKANOLAMINE, A BASIC AMINO ACID AND A SUITABLY SELECTED ADDITIONAL ALKALINE AGENT - The present invention relates to a composition for treating keratin fibres, and in particular human keratin fibres such as the hair, comprising, in a cosmetically acceptable medium, one or more alkanolamines, one or more basic amino acids and one or more additional alkaline agents chosen from aqueous ammonia; ammonium salts of acids whose pKa at 25° C. is greater than 4; alkali metal or alkaline-earth metal hydroxides, carbonates, carbamates and hydrogen carbonates. The present invention also relates to processes for bleaching and/or dyeing keratin fibres, and also to multi-compartment devices or ‘kits’ for performing these processes. | 2011-06-23 |
20110150798 | COMPOSITIONS AND METHODS FOR INCREASING CELLULAR FAR AND BLEACHING SKIN - Compositions and methods are disclosed for the treatment of cells, such as keratinocytes and adipocytes, to increase their lipid content and compositions and methods are disclosed for treatment of skin cells to diminish the appearance of blemishes. | 2011-06-23 |
20110150799 | Block Copolymer and Ester-Terminated Polyesteramide Composition and Uses Thereof - Compositions and methods for the preparation of a composition comprising a block copolymer and ester-terminated polyester amide solubilized in a compatible solvent are disclosed. The disclosed compositions are long-lasting, transfer resistant, flexible, and water-proof capable of complexing the active ingredient to provide such benefits. The disclosed compositions are useful for formulating cosmetics, personal care products, cosmeceuticals, and the like. | 2011-06-23 |
20110150800 | W/O EMULSION WITH EMULSIFYING SILICONE ELASTOMER AND VOLATILE LINEAR ALKANE - Composition particularly useful for caring for and/or making up keratin materials, in particular the skin, in the form of a water-in-oil emulsion containing water and:
| 2011-06-23 |
20110150801 | COLOURED COMPOSITION FOR CONCEALING SKIN IMPERFECTIONS - A coloured composition useful for making up keratinous substances, in particular the skin, in the form of a water-in-oil emulsion containing at least 18% by weight of pulverulent colouring materials, with respect to the total weight of the composition, and at least one or more volatile linear alkanes, in particular C | 2011-06-23 |
20110150802 | COMPOSITION CONTAINING AN AQUEOUS DISPERSION OF POLYURETHANE AND AN OIL-SOLUBLE POLAR MODIFIED POLYMER - The invention relates to a composition comprising at least one aqueous polyurethane dispersion, at least one oil-soluble polar modified polymer, and at least one polyamine compound having at least two amine groups. | 2011-06-23 |
20110150803 | EQUILIBRATED DYNAMIC MIXTURES CONTAINING STABILIZED HEMIACETALS FOR THE CONTROLLED RELEASE OF ACTIVE ALCOHOLS - The present invention concerns a dynamic mixture containing stabilized hemiacetals obtainable by combining at least one specific aldehyde derivative with at least one active alcohol and optionally a stabilizing salt. The dynamic mixture is capable of releasing into the surrounding environment and in a controlled and prolonged manner an active compound such as a perfuming or flavoring ingredient. | 2011-06-23 |
20110150804 | HAIR TREATMENT COMPOSITION - The present invention is a hair treatment composition containing components (a) and (b): (a) a compound having 2 or 3 amino acid residues and represented by general Formula (1), or a salt thereof [in the formula, X denotes a divalent hydrocarbon group having 1 to 4 carbon atoms, which may be substituted with a hydroxy group, or a specific amino acid residue, Y denotes a specific amino acid residue or a divalent group represented by chemical Formula (2) (in the formula, —* denotes a direct bond bonding to an adjacent carbonyl group or oxygen atom), R denotes a hydrogen atom or a monovalent hydrocarbon group having 1 to 4 carbon atoms, which may be substituted with a hydroxy group, m and n denote 0 or 1, and when m and n are simultaneously 1, X is not an amino acid residue]; and (b) an aliphatic carboxylic acid having no greater than 8 carbon atoms or a salt thereof. | 2011-06-23 |
20110150805 | MAKEUP COMPOSITION - Composition for making up keratin fibres, such as eyelashes or eyebrows, having improved makeup-removing properties, containing in a continuous aqueous phase:
| 2011-06-23 |
20110150806 | COMPOSITION CONTAINING AN AQUEOUS DISPERSION OF POLYURETHANE AND AN OIL-SOLUBLE POLAR MODIFIED POLYMER - The invention relates to a composition comprising at least one aqueous polyurethane dispersion, at least one oil-soluble polar modified polymer, at least one alkoxylated fatty alcohol, and at least one polyamine compound having at least two amine groups. | 2011-06-23 |
20110150807 | MASCARA CONTAINING AQUEOUS DISPERSION OF POLYURETHANE AND A HARD WAX - The invention relates to a composition comprising aqueous polyurethane dispersions and at least one hard wax. | 2011-06-23 |
20110150808 | METHOD FOR MANUFACTURE OF PIGMENT-CONTAINING COSMETIC COMPOSITIONS AND RELATED COMPOSITIONS - The present invention relates to pigment colorants and more directly to a pigment composition comprising a pigment treated with a water-dispersible polyester or polyesteramide polymer in the presence of added water. The invention also relates to a method grinding a mixture containing a pigment with a water-dispersible polyester or polyesteramide in the presence of added water. Such pigment compositions are particularly useful as the colorant in cosmetic composition | 2011-06-23 |
20110150809 | COMPOSITION CONTAINING AT LEAST ONE VOLATILE LINEAR ALKANE AND AT LEAST ONE CATIONIC SURFACTANT - Composition containing, in a cosmetically acceptable medium, at least 2.5% by weight of one or more volatile linear alkanes relative to the total weight of the composition, and one or more cationic surfactants, where the volatile linear alkane(s)/cationic surfactant(s) weight ratio is less than or equal to 1.5. Use of this composition for the treatment of keratin materials, preferably the hair. | 2011-06-23 |
20110150810 | CONDITIONING COMPOSITION FOR HAIR - The present invention is related to aqueous conditioning composition for hair comprising at least one alkyl glyceryl ether and at least one silicone compound with at least one quaternary ammonium group in its molecule. Conditioning composition of the present invention can be in the form of a shampoo, cleansing-conditioning composition, or in the form of a conditioner used after washing hair with cleansing compositions. It has surprisingly been found out that a composition comprising at least one alkyl glyceryl ether and at least one silicone compound with at least one quaternary ammonium group in its molecule gives hair shine, volume and body and hair treated with such a composition looks attractive and has its natural excellent shine, volume and body, elasticity, smoothness and it is easily manageable. Accordingly, present invention is on a conditioning composition for hair comprising at least one alkyl glyceryl ether and at least one silicone compound with at least one quaternary ammonium group in its molecule. | 2011-06-23 |
20110150811 | COMPOSITION CONTAINING AT LEAST ONE VOLATILE LINEAR ALKANE, AT LEAST ONE SILICONE AND AT LEAST ONE FATTY SUBSTANCE - Composition containing, in an aqueous medium:
| 2011-06-23 |
20110150812 | NATURAL CONDITIONING COSMETIC COMPOSITIONS - A composition and method of enhancing the appearance of a keratinous material involving the steps of: (a) providing a composition containing: (a) at least one colloidal agent comprising a combination of: (A) at least one microcrystalline cellulose compound and (B) at least one hydrocolloid compound, and wherein (A) is present in an amount greater than (B); (b) at least one polysaccharide; (c) at least one polyol ester; (d) optionally, at least one viscosity-modifying hydrocolloid; and (e) optionally, at least one emulsifier; and (f) a cosmetically acceptable carrier. | 2011-06-23 |
20110150813 | COSMETIC COMPOSITION IN THE FORM OF A NANOEMULSION CONTAINING A VOLATILE LINEAR ALKANE - Composition in the form of an oil-in-water nanoemulsion containing one or more nonionic amphiphilic lipids, one or more volatile linear alkanes and one or more oils other than the volatile linear alkane(s). | 2011-06-23 |
20110150814 | MALODOR CONTROL COMPOSITION HAVING A MIXTURE OF VOLATILE ALDEHYDES AND METHODS THEREOF - A malodor control composition having a mixture of volatile aldehydes and methods thereof are provided. The composition is suitable for a variety of applications, including use in fabric and air freshening products. | 2011-06-23 |
20110150815 | MALODOR CONTROL COMPOSITION HAVING AN ACID CATALYST AND METHODS THEREOF - A malodor control composition having at least one volatile aldehyde and an acid catalyst, and methods thereof are provided. The malodor control composition is suitable for a variety of applications, including use in fabric and air freshening products. | 2011-06-23 |
20110150816 | METHOD OF NEUTRALIZING MALODORS - A method of neutralizing malodors by providing a malodor control composition having a mixture of volatile aldehydes is provided. In some embodiments, the malodor control composition includes an acid catalyst. | 2011-06-23 |
20110150817 | FRESHENING COMPOSITIONS COMPRISING MALODOR BINDING POLYMERS AND MALODOR CONTROL COMPONENTS - Freshening compositions comprising a malodor binding polymer, malodor control components, and an aqueous carrier; and methods thereof are provided. In some embodiments, the freshening composition comprises a homopolymeric polyethylenimine having a molecular weight of about 1,000 to about 2,000,000 and a mixture of volatile aldehydes. Such freshening compositions may be used to reduce malodor and/or microbes on inanimate surfaces or in the air. | 2011-06-23 |
20110150818 | Silicone-Organic Hybrid Emulsions In Personal Care Applications - Personal care compositions containing silicone polymer and organic polymer containing alloy and/or hybrid emulsions are disclosed. The silicone organic hybrid emulsions are particularly useful in hair care formulations to simultaneously provide conditioning and styling benefits. The silicone organic hybrid emulsions are also useful in color cosmetic formulations to provide shine and wash-off resistance benefits. | 2011-06-23 |
20110150819 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE DERIVATIVES - Disclosure is provided for imidazole derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions comprising these compounds, devices comprising these compounds, and methods of using the same. | 2011-06-23 |
20110150820 | METHODS FOR COVALENTLY ATTACHING A POLYMER TO A METHIONINE RESIDUE IN PROTEINS AND PEPTIDES - Conjugates of polypeptides and a polymeric moiety such as PEG covalently attached to the sulfur atom of a methionine side chain are disclosed. Processes of preparing such conjugates, including intermediates and reagents utilized therefore are also disclosed. Further disclosed are therapeutic uses of these conjugates. | 2011-06-23 |
20110150821 | METHODS AND CROSSLINKED POLYMER COMPOSITIONS FOR CARTILAGE REPAIR - A method of repairing damaged cartilage and soft tissue in a patient is provided using a biocompatible, non-immunogenic composition. The composition comprises a hydrophilic polymer and a plurality of crosslinkable components having reactive functional groups. The composition used in the method may be loaded with biologically active agents for delivery to the damaged tissues. Kits for use in carrying out the method of the invention are also provided. | 2011-06-23 |
20110150822 | PHEROMONE COMPOSITIONS AND METHODS OF USE - Pheromone compositions based on a combination of squalene, linoleic acid and 1-docosanol are described. The compositions are useful for behavior modification in mammals that exhibit undesirable or harmful stress-related behaviors. | 2011-06-23 |
20110150823 | Cell Tissue Gel Containing Collagen and Hyaluronan - A cell tissue gel containing collagen and hyaluronan at a weight ratio of 0.01-100:1 and uses thereof for stem cell delivery. | 2011-06-23 |
20110150824 | Nutritional Composition for Improving the Mammalian Immune System - The invention relates to a nutritional composition comprising
| 2011-06-23 |
20110150825 | USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS - Described herein are methods for treating a subject suffering from an inflammatory, autoimmune, or heteroimmune condition by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a compound that is a selective inhibitor of histone deacetylase 8. Also described herein are methods for decreasing secretion of pro-inflammatory cytokines by administering an HDAC8-selective inhibitor compound. Further described herein are methods for predicting responsiveness to treatments for inflammatory conditions. Methods for predicting efficacy of treatments for inflammatory conditions are also described. | 2011-06-23 |
20110150826 | AGENT FOR THE TREATMENT AND/OR PROPHYLAXIS OF AN AUTOIMMUNE DISEASE AND FOR THE FORMATION OF REGULATORY T CELLS - The present invention relates to an agent for the treatment and/or prophylaxis of an autoimmune disease, an agent for the formation of regulatory T cells (T | 2011-06-23 |
20110150827 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS - Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. | 2011-06-23 |
20110150828 | INTERLEUKIN-2/SOLUBLE TGF-BETA TYPE II RECEPTOR B CONJUGATES AND METHODS AND USES THEREOF - A conjugate protein comprising an IL-2 and a soluble TGF-beta type II receptor type B and its use in cancer immunotherapy are described. | 2011-06-23 |
20110150829 | ANTIVIRAL NUCLEOSIDES - Compounds having the formula I wherein R | 2011-06-23 |
20110150830 | COVALENT CONJUGATES BETWEEN ENDOPEROXIDES AND TRANSFERRIN AND LACTOFERRIN RECEPTOR-BINDING AGENTS - The invention relates to covalent conjugates between endoperoxides and small peptides and organic compounds that bind to molecular cavities on the transferrin or lactoferrin receptor, and the use of compositions comprising these conjugates to treat cancer, hyperproliferative disorders, inflammatory diseases, and infections. | 2011-06-23 |
20110150831 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS - The present invention relates to kinase modulators of the naphthyridine type and to the preparation and use thereof as medicaments for the modulation of misdirected cellular signal transduction processes, in particular for influencing the function of tyrosine and serine/threonine kinases and for the treatment of malignant or benign tumours and other disorders based on pathological cell proliferation, such as, for example, restenosis, psoriasis, arteriosclerosis and cirrhosis of the liver. | 2011-06-23 |
20110150832 | FURIN-KNOCKDOWN BI-FUNCTIONAL RNA - Compositions and methods to attenuate the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs is described herein. The bi-functional shRNAs of the present invention knocks down the expression of furin in cancer cells to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene. | 2011-06-23 |
20110150833 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS - Compounds useful as Rho kinase inhibitors of formula (1) wherein the variables are as defined herein are provided. Methods of treatment of malconditions mediated by Rho kinase, and methods of preparation of the compounds, are also provided. | 2011-06-23 |
20110150834 | CRTH2 MODULATORS - Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed. The compounds fall within a genus described by formula I: | 2011-06-23 |
20110150835 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease - The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. | 2011-06-23 |
20110150836 | METHODS OF TREATING HBV AND HCV INFECTION - This application relates to a purine derivative and pharmaceutical compositions which are useful for treating a hepatitis B viral infection or a hepatitis C viral infection. | 2011-06-23 |
20110150837 | Amphiphilic polymer functionalized by methionine - The present invention relates to new amphiphilic polymers comprising hydrophobic groups and methionine groups. | 2011-06-23 |
20110150838 | LACTOBACILLUS PARACASEI STRAIN LT12 AS IMMUNITY REGULATORY AGENT - An isolated | 2011-06-23 |
20110150839 | METHOD TO OBTAIN TRANSGENIC PLANTS RESISTANT TO PHYTOPATHOGEN ATTACK BASED ON RNA INTERFERENCE (RNA) - The present invention relates to a method to obtain transgenic plants resistant to the attack of phytopathogens (i.e. parasites and phytophages) based on RNA interference, which contemplates the expression of double strand RNA (dsRNA) in the plant tissues, suitable for inhibiting the functionality of a GPCR receptor, whose functioning is vital for fungi, herbivorous insects or phytopathogenic nematodes. | 2011-06-23 |
20110150840 | Detection and Treatment of Glyco-Enzyme-Related Disease - The present invention relates to the prevention and treatment of a disease, preferably brain cancer, by administration of an isolated DNA molecule comprising a gene encoding a protein having glycosyltransferase activity to a cell involved in the disease which is preferably a glioblastoma cell. A method of treating brain cancer is provided in which a tumor cell is transfected either ex vivo or in vivo with a composition comprising a DNA molecule that encodes a protein having glycosyltransferase activity resulting in inhibition of the growth or function of that cell. | 2011-06-23 |
20110150841 | Secretion System and Methods for its Use - The present invention provides reagents and methods for inhibiting bacterial infection and abnormal cell growth, as well as for selection cloning of nucleic acid inserts. | 2011-06-23 |
20110150842 | Derivation of Embryonic Stem Cells - This present invention provides novel methods for deriving embryonic stem cells, those cells and cell lines, and the use of the cells for therapeutic and research purposes without the destruction of the embryo. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF. | 2011-06-23 |
20110150843 | METHOD FOR THE THERAPEUTIC CORRECTION OF HEMOPHILIA A BY TRANSPLANTING BONE MARROW CELLS - The transdifferentiation of bone marrow cells (BMCs) into hepatocytes can be used for the development of cellular medicine for degenerative and genetic diseases. Since the liver is the primary site of factor VIII (FVIII) synthesis, the partial replacement of mutated liver cells by healthy cells in hemophilia A (HA) could manage the severity of the bleeding disorder. The use of BMCs could be used as a therapy for the bleeding phenotype of hemophilia A and other related disorders. | 2011-06-23 |
20110150844 | COMPOSITIONS AND METHODS FOR CONTROLLING PROLIFERATION AND DIFFERENTIATION OF CELLS - Methods and compositions for modulating cell differentiation, proliferation and morphology in vitro or in vivo are described. The methods include modifying the extracellular nanoenvironment of stem cells with a self-assembling peptide nanofiber scaffold. The extracellular nanoenvironment can be modified by changing the percentage of self-assembling peptides used to form the nanofiber scaffold, the concentration of cells in the nanofiber scaffold, the pH, or the amounts of serum. Modulating the extracellular nanoenvironment of cells in nanofiber scaffold allows for increased targeting of cell placement and therapeutic delivery, amplified by cell encapsulation and implantation. | 2011-06-23 |
20110150845 | METHODS AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE - The invention provides compositions and methods for modulating immune responses using mesenchymal stem cells. The invention further provides methods for inducing tolerance to self antigens using mesenchymal stem cells. | 2011-06-23 |
20110150846 | COMPOSITIONS AND METHODS FOR TISSUE FILLING AND REGENERATION - Injectable compositions are provided which include both a living cellular component and a filler component conducive to cell growth. The compositions are capable of providing both immediate tissue filling and long term tissue regeneration. | 2011-06-23 |
20110150847 | METHOD OF THREE-DIMENSIONALLY CULTURING CHONDROCYTES - It is intended to provide a method of three-dimensionally culturing normal joint chondrocytes; the production and supply of chondrocytes; and a transplantation material to be used in an injured site in a joint tissue. | 2011-06-23 |
20110150848 | Cell Suspension Preparation Technique and Device - The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a patient are collected and dispersed in a solution that is suitable for immediate dispersion over the recipient graft site. | 2011-06-23 |
20110150849 | Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules - The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 2011-06-23 |
20110150850 | REDUCED COLONIZATION OF MICROBES AT THE MUCOSA - The invention is in the field of use of engineered microbes for the delivery and administration of therapeutic peptides or proteins to humans or animals suffering from a disease, or the use of engineered microbes for the delivery of antigens such as for vaccination purposes. More in particular, the invention relates to a recombinant microbe that has reduced capacity of colonizing the mucosa in comparison to its wild type ancestor, in particular when residing in the alimentary tract as part of a treatment or vaccination of a human or animal. In particular, the recombinant microbe contains an inactive thymidylate synthase gene that causes the reduced capability for the microbe to colonize in the alimentary tract. The invention also covers the use of said recombinant microbes comprising nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to animals or humans. | 2011-06-23 |
20110150851 | NUTRITIONAL COMPOSITION FOR INFANTS DELIVERED VIA CAESAREAN SECTION - The present invention relates to compositions to be administered to infants delivered via caesarean section and in particular to a product comprising inactivated cells and/or bacterial cell fragments of Gram-negative bacteria and of optionally inactivated Gram-positive bacteria. Thereby it is possible to stimulate a fast colonisation of the intestinal microbiota of said infants. | 2011-06-23 |
20110150852 | Novel Strain of Lactobacillus Paracasei Subspecies Paracasei Having Antimicrobial and Immunomodulatory Properties - The invention relates to a novel strain of | 2011-06-23 |
20110150853 | MYCOTOXIN-REDUCING COMPOSITION - A composition comprising an enzyme, a mycotoxin-binding agent and a microorganism capable of taking up a mycotoxin. | 2011-06-23 |
20110150854 | RIBOSWITCHES, METHODS FOR THEIR USE, AND COMPOSITIONS FOR USE WITH RIBOSWITCHES - It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new non-immunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen—turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments. | 2011-06-23 |
20110150855 | Enzyme Composition and Use Thereof - Disclosed is a means effective for the treatment or prevention of inflammatory bowel disease. Specifically disclosed is an enzyme composition for the treatment or prevention of inflammatory bowel disease, which utilizes an enzyme capable of producing an oligosaccharide in vivo. | 2011-06-23 |
20110150856 | COMPOSITIONS AND METHODS FOR TREATMENT OF VITILIGO - Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen. | 2011-06-23 |
20110150857 | PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2011-06-23 |
20110150859 | METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS - The present invention relates to a method for identifying responders to a blockade of integrin receptors, as well as to a method for determining responsiveness to a treatment involving with said blockade in a patient in need of such treatment. Furthermore, the present invention relates to a kit for use in said methods. | 2011-06-23 |
20110150860 | NOVEL 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 AND 49933 MOLECULES AND USES THEREFOR - The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 2011-06-23 |
20110150861 | SORF CONSTRUCTS AND MULTIPLE GENE EXPRESSION - Embodiments of the invention relate to vector constructs and methods for expression of polypeptides including multimeric products such as therapeutic antibodies. Particular constructs allow for the generation of expression products from a single open reading frame (sORF). An embodiment provides an isolated or purified expression vector for generating one or more recombinant protein products comprising a single open reading frame insert; said insert comprising a signal peptide nucleic acid sequence encoding a signal peptide; a first nucleic acid sequence encoding a first polypeptide; a first intervening nucleic acid sequence encoding a first protein cleavage site, wherein said first protein cleavage site is provided by an intein segment of a Ion protease gene of | 2011-06-23 |
20110150862 | INHIBITORS OF STIM1 FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS - The invention relates to inhibitors of STIM1 for the treatment and/or the prevention of cardiac disorders such as atherosclerosis, post-angioplasty restenosis, pulmonary arterial hypertension, vein-graft disease, cardiac hypertrophy, cardiac arrhythmias, valvulopathies, diastolic dysfunction, chronic heart failure, ischemic heart failure, and myocarditis. | 2011-06-23 |
20110150863 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES - The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5′ end. | 2011-06-23 |
20110150864 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS - The present invention relates to compounds of Formula (I), | 2011-06-23 |
20110150865 | ANTIBODIES TO LYMPHOTOXIN-ALPHA - The invention provides various antibodies that bind to lymphotoxin-α, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies. | 2011-06-23 |
20110150866 | Compositions and Methods for Increasing Bone Mineralization - A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules. | 2011-06-23 |
20110150867 | POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS - The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody. | 2011-06-23 |
20110150868 | DIAGNOSTIC AND THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING PTEN AND BREAST CANCER - Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab. | 2011-06-23 |
20110150869 | Neuroinvasion Inhibitor - The present inventors discovered that neural invasion is suppressed by inhibiting IL-6 in a model for neural invasion of pancreatic cancer, and completed the present invention. The present inventors also demonstrated that: an IL-6 receptor is expressed in cells of human pancreatic cancer cell lines; and IL-6 enhances the chemotactic and migratory activities and intracellular signaling of pancreatic cancer cells; and thus pancreatic cancer can be treated by inhibiting IL-6. Furthermore, the present inventors found that neural invasion of human pancreatic cancer can be suppressed, from the results of administering IL-6 inhibitors to neural invasion model mice. | 2011-06-23 |
20110150870 | FULLY HUMAN ANTI-HUMAN NKG2D MONOCLONAL ANTIBODIES - The invention relates to isolated fully human monoclonal antibodies having specificity for human NKG2D and compositions thereof. The invention further relates to methods for using such antibodies in treating diseases or conditions such as cancer, autoimmune disease, or infectious disease. | 2011-06-23 |